Dr. Lal PathLabs’ Board has approved a ₹3.5 interim dividend per share. Additionally, the board greenlit the allotment of 4,000 equity shares under its Employee Stock Option Plan 2010. The company’s financial results for Q3 2026 were also approved. The decisions occurred during the board meeting on January 30, 2026.
Interim Dividend Declared
Dr. Lal PathLabs’ Board of Directors has declared a third interim dividend of ₹3.5 per equity share, representing 35% on a face value of ₹10 each for fiscal year 2025-26. The record date for dividend payment is February 5, 2026. Payment will occur within 30 days.
Equity Shares Allotted
The company has allotted 4,000 equity shares under its Employee Stock Option Plan 2010. Following the allotment, the paid-up equity share capital of the company has increased to ₹1,67,55,50,200, divided into 16,75,55,020 equity shares of ₹10 each.
Financial Performance Highlights
The Board approved the unaudited consolidated and standalone financial results for Q3 2026 and the nine months ending December 31, 2025.
Financial snapshot (Consolidated):
Revenue from operations: ₹6,598 million
Total income: ₹6,842 million
Profit before tax: ₹1,243 million
Profit for the period: ₹914 million
Financial snapshot (Standalone):
Revenue from operations: ₹6,321 million
Total income: ₹6,587 million
Profit before tax: ₹1,231 million
Profit for the period: ₹921 million
Source: BSE
